Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19
Lancet Respir Med
.
2021 Nov;9(11):1207-1209.
doi: 10.1016/S2213-2600(21)00366-0.
Epub 2021 Aug 13.
Author
Christopher D Richardson
1
Affiliation
1
Department of Microbiology & Immunology/Pediatrics, Canadian Center of Vaccinology, Dalhousie University, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: chris.richardson@dal.ca.
PMID:
34391548
PMCID:
PMC8360699
DOI:
10.1016/S2213-2600(21)00366-0
No abstract available
MeSH terms
BNT162 Vaccine* / immunology
COVID-19* / prevention & control
Humans
Immunogenicity, Vaccine*
Vaccination
Substances
BNT162 Vaccine